The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Circulating and extramedullary disease in myeloma: biology and emerging treatments
Saurabh Zanwar, MD, MBBS, Mayo Clinic, Rochester, MN, Darren Pan, MD, UCSF Health, San Francisco, CA, and Niels Weinhold, PhD, University Hospital Heidelberg, Heidelberg, Germany, discuss the biological characteristics and treatment challenges of extramedullary disease in multiple myeloma. The panel explores differences between true extramedullary and paraskeletal disease, genomic signatures and disease proliferation, as well as emerging treatment strategies involving CAR T-cell therapy, bispecific antibodies, and intensive bridging chemotherapy. This discussion took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
